Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 6/20 | 0.50 |
| ▸ | CDC25A | P30304 | 4/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | S100A4 | P26447 | 5/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14459554 | 0.85 | MAPT (0.41) | MAPTKDM4EALDH1A1LMNAHTT | |
| SCHEMBL3271510 | 0.84 | CDC25B (0.55) | MAPTKDM4EALDH1A1LMNAHTT | |
| SCHEMBL5820368 | 0.83 | MAPT (0.58) | MAPTKDM4EALDH1A1LMNAHTT | |
| SCHEMBL5810540 | 0.83 | TBXAS1 (0.62) | MAPTKDM4EALDH1A1LMNAHTT | |
| SCHEMBL571496 | 0.81 | MAPT (0.56) | MAPTKDM4EALDH1A1LMNAHTT | |
| SCHEMBL10446741 | 0.79 | MAPT (0.59) | MAPTKDM4EALDH1A1LMNAHTT | |
| SCHEMBL3271230 | 0.79 | AURKA (0.55) | MAPTKDM4EALDH1A1LMNAHTT | |
| SCHEMBL13649286 | 0.79 | MAPT (0.54) | MAPTKDM4EALDH1A1LMNAHTT | |
| SCHEMBL571005 | 0.78 | MAPT (0.53) | MAPTKDM4EALDH1A1LMNAHTT | |
| SCHEMBL29941466 | 0.77 | CDC25B (0.68) | MAPTKDM4EALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107226789-A | Dithiocarbamates compound, its preparation method and the purposes in antineoplastic is prepared | 北京大学 | 2017-10-03 | — | — | CN | claimed |
| US-20220348530-A1 | Menaquinol Compositions and Methods of Treatment | Epizon Pharma, Inc. (US) | 2022-11-03 | — | — | US | disclosed |
| US-11332427-B2 | Menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210009494-A1 | Menaquinol Compositions and Methods of Treatment | Epizon Pharma, Inc. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10822295-B2 | Menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| CN-107226789-B | Dithiocarbamates compound, preparation method and purposes in the preparation of antitumor drugs | 北京大学 | 2019-11-08 | — | — | CN | disclosed |
| CN-107226789-A | Dithiocarbamates compound, its preparation method and the purposes in antineoplastic is prepared | 北京大学 | 2017-10-03 | — | — | CN | disclosed |
| WO-2013036766-A1 | SMALL MOLECULE NAPHTHOQUINONE- AND PHTHALIMIDE-BASED LIPOCATIONS AS ANTI-PARASITIC AGENTS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-8124793-B2 | Derivatives of ethylene methanedisulfonate as cancer chemotherapeutic agents | CRONYN MARSHALL W (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | CRONYN MARSHALL W | 2009-07-09 | — | — | US | disclosed |
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2007095630-A2 | NEW UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009494-A1 | Menaquinol Compositions and Methods of Treatment | SDHA, SDHB, NDUFB7 | MAPT 3333/4885KDM4E 1697/4885ALDH1A1 762/4885 |
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | NDUFB7, NDUFB1, NDUFB3 | MAPT 4254/4885KDM4E 2305/4885ALDH1A1 638/4885 |
| US-20220348530-A1 | Menaquinol Compositions and Methods of Treatment | SDHA, SDHB, NDUFB7 | MAPT 3333/4885KDM4E 1697/4885ALDH1A1 762/4885 |
| US-11332427-B2 | Menaquinol compositions and methods of treatment | SDHA, SDHB, NDUFB7 | MAPT 3333/4885KDM4E 1697/4885ALDH1A1 762/4885 |
| US-10822295-B2 | Menaquinol compositions and methods of treatment | PROC, VKORC1L1, VKORC1 | MAPT 2533/4885KDM4E 1672/4885ALDH1A1 1954/4885 |
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | MGMT, ETV6, EI24 | MAPT 4552/4885KDM4E 1323/4885ALDH1A1 2643/4885 |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | NDUFB5, NDUFB7, NDUFB3 | MAPT 1404/4885KDM4E 3016/4885ALDH1A1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.